Measurement of Myofilament-Localized Calcium Dynamics in Adult Cardiomyocytes and the Effect of Hypertrophic Cardiomyopathy Mutations

Circ Res. 2019 Apr 12;124(8):1228-1239. doi: 10.1161/CIRCRESAHA.118.314600.

Abstract

Rationale: Subcellular Ca2+ indicators have yet to be developed for the myofilament where disease mutation or small molecules may alter contractility through myofilament Ca2+ sensitivity. Here, we develop and characterize genetically encoded Ca2+ indicators restricted to the myofilament to directly visualize Ca2+ changes in the sarcomere.

Objective: To produce and validate myofilament-restricted Ca2+ imaging probes in an adenoviral transduction adult cardiomyocyte model using drugs that alter myofilament function (MYK-461, omecamtiv mecarbil, and levosimendan) or following cotransduction of 2 established hypertrophic cardiomyopathy disease-causing mutants (cTnT [Troponin T] R92Q and cTnI [Troponin I] R145G) that alter myofilament Ca2+ handling.

Methods and results: When expressed in adult ventricular cardiomyocytes RGECO-TnT (Troponin T)/TnI (Troponin I) sensors localize correctly to the sarcomere without contractile impairment. Both sensors report cyclical changes in fluorescence in paced cardiomyocytes with reduced Ca2+ on and increased Ca2+ off rates compared with unconjugated RGECO. RGECO-TnT/TnI revealed changes to localized Ca2+ handling conferred by MYK-461 and levosimendan, including an increase in Ca2+ binding rates with both levosimendan and MYK-461 not detected by an unrestricted protein sensor. Coadenoviral transduction of RGECO-TnT/TnI with hypertrophic cardiomyopathy causing thin filament mutants showed that the mutations increase myofilament [Ca2+] in systole, lengthen time to peak systolic [Ca2+], and delay [Ca2+] release. This contrasts with the effect of the same mutations on cytoplasmic Ca2+, when measured using unrestricted RGECO where changes to peak systolic Ca2+ are inconsistent between the 2 mutations. These data contrast with previous findings using chemical dyes that show no alteration of [Ca2+] transient amplitude or time to peak Ca2+.

Conclusions: RGECO-TnT/TnI are functionally equivalent. They visualize Ca2+ within the myofilament and reveal unrecognized aspects of small molecule and disease-associated mutations in living cells.

Keywords: calcium; cardiomyopathies; fluorescence; mutation; sarcomere.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphatases / antagonists & inhibitors
  • Adenosine Triphosphatases / metabolism
  • Adenoviridae
  • Animals
  • Benzylamines / pharmacology
  • Calcium / metabolism*
  • Cardiomyopathy, Hypertrophic / genetics*
  • Cardiomyopathy, Hypertrophic / metabolism
  • Guinea Pigs
  • In Vitro Techniques
  • Male
  • Mutation*
  • Myocytes, Cardiac / metabolism*
  • Myofibrils / drug effects
  • Myofibrils / metabolism*
  • Myosins / drug effects
  • Myosins / metabolism
  • Sarcomeres / metabolism*
  • Simendan / pharmacology
  • Transduction, Genetic / methods
  • Troponin I / genetics
  • Troponin I / metabolism
  • Troponin T / genetics
  • Troponin T / metabolism
  • Uracil / analogs & derivatives
  • Uracil / pharmacology
  • Urea / analogs & derivatives
  • Urea / pharmacology

Substances

  • Benzylamines
  • MYK-461
  • Troponin I
  • Troponin T
  • omecamtiv mecarbil
  • Simendan
  • Uracil
  • Urea
  • Adenosine Triphosphatases
  • Myosins
  • Calcium